753 related articles for article (PubMed ID: 15314994)
1. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
[TBL] [Abstract][Full Text] [Related]
2. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease.
Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):242-7. PubMed ID: 15314993
[TBL] [Abstract][Full Text] [Related]
4. [Thyrotropin receptor antibodies (TRAb) as a test of surgical treatment effectiveness in Graves-Basedow's diseases].
Bojarska-Szmygin A; Ciechanek R; Jezierska B; Zaorska-Rajca J
Pol Merkur Lekarski; 2002 Sep; 13(75):196-9. PubMed ID: 12474569
[TBL] [Abstract][Full Text] [Related]
5. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
Rink T; Holle LH; Schroth HJ; Garth H
Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
[TBL] [Abstract][Full Text] [Related]
6. [The effect of thyrostatic treatment on circulating thyrotropin-receptor antibodies in Basedow's disease].
Lozanov B; Kirilov G; Ivanova R; Khubaveshki S
Vutr Boles; 1990; 29(3):79-84. PubMed ID: 1704667
[TBL] [Abstract][Full Text] [Related]
7. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
8. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
Gauna AT; Guillén CE; Sartorio GC; Soto RJ
Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
[TBL] [Abstract][Full Text] [Related]
10. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
[TBL] [Abstract][Full Text] [Related]
11. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
12. [TSH anti-receptor antibodies in Graves' disease].
Sérgio MR; Godinho C; Guerra L; Agapito A; Fonseca F; Costa C
Acta Med Port; 1996; 9(7-9):229-31. PubMed ID: 9005701
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
15. [Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options].
Campos Pastor MM; Fernández Soto ML; Escobar-Jiménez F; Barredo Acedo F; Ruiz de Almodóvar M
Med Clin (Barc); 1994 Apr; 102(12):446-50. PubMed ID: 7516033
[TBL] [Abstract][Full Text] [Related]
16. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
17. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
18. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
[TBL] [Abstract][Full Text] [Related]
19. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
[TBL] [Abstract][Full Text] [Related]
20. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
